TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 25962765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis

  2015cited by this paper
• Independent Relationship of Osteoprotegerin Concentrations with Endothelial Activation and Carotid Atherosclerosis in Patients with Severe Rheumatoid Arthritis

  2014cited by this paper
• Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis

  2013cited by this paper
• The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis.

  2013cited by this paper
• Prognostic Value of TNF-Related Apoptosis Inducing Ligand (TRAIL) in Acute Coronary Syndrome Patients

  2013cited by this paper
• Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced?

  2013cited by this paper
• C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway

  2013cited by this paper
• Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study

  2012cited by this paper
• Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.

  2012cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe−/− mice

  2011cited by this paper
• Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis.

  2011cited by this paper
• Circulating TRAIL Shows a Significant Post-Partum Decline Associated to Stressful Conditions

  2011cited by this paper
• TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice

  2011cited by this paper
• TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis.

  2011cited by this paper
• Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs

  2010cited by this paper
• 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

  2010cited by this paper
• Subclinical peripheral arterial disease in rheumatoid arthritis.

  2010cited by this paper
• Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction

  2009cited by this paper
• Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

  2008cited by this paper
• Prognostic value of apoptosis markers in advanced heart failure patients.

  2008cited by this paper
• Preliminary clinical measurement of the expression of TNF‐related apoptosis inducing ligand in patients with ankylosing spondylitis

  2008cited by this paper
• Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis.

  2007cited by this paper
• HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis.

  2007cited by this paper
• Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.

  2007cited by this paper
• Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome: Possible Role in Plaque Destabilization

  2006cited by this paper
• Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.

  2006cited by this paper
• Systemic Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E–Null Diabetic Mice

  2006cited by this paper
• The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.

  2005cited by this paper
• The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.

  2005cited by this paper
• TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy.

  2005cited by this paper
• Rheumatoid arthritis: a disease associated with accelerated atherogenesis.

  2005cited by this paper
• Emerging non‐apoptotic functions of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)/Apo2L

  2004cited by this paper
• Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease

  2004cited by this paper
• TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells

  2004cited by this paper
• Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis

  2003cited by this paper
• National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification

  2003cited by this paper
• High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.

  2002cited by this paper
• Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure.

  2002cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper

• Identifying Targets and Drugs for Rheumatoid Arthritis Stratified Therapy Using Mendelian Randomization and a Pretraining Model

  2025cites this paper
• Serum markers of cardiac complications in a systemic sclerosis cohort

  2021cites this paper
• HIF-1α Mediates TRAIL-Induced Neuronal Apoptosis via Regulating DcR1 Expression Following Traumatic Brain Injury

  2020cites this paper
• TRAIL: A novel atheroprotective mechanism in the vasculature

  2019cites this paper
• TRAIL protects against endothelial dysfunction in vivo and inhibits angiotensin‐II‐induced oxidative stress in vascular endothelial cells in vitro

  2018cites this paper
• Tumour necrosis factor-related apoptosis-inducing ligand expression in patients with diabetic nephropathy

  2018cites this paper
• Effect of adjuvant therapy with ginkgo-damole on apoptosis, nerve injury and platelet aggregation of patients with acute cerebral infarction

  2017cites this paper
• Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro

  2017cites this paper
• Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers.

  2016cites this paper
• Decreased expression of methylene tetrahydrofolate reductase (MTHFR) gene in patients with rheumatoid arthritis.

  2016cites this paper
• Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis

  2016cites this paper
• Association of homocysteine with immunological-inflammatory and metabolic laboratory markers and factors in relation to hyperhomocysteinaemia in rheumatoid arthritis.

  2015cites this paper